Valsartan Intensified Primary Care Reduction of Blood Pressure Study

Completed · Phase 4

Conditions studied: Hypertension

In brief

This study will assess the efficacy of an intensive blood pressure management strategy compared to usual care in a primary care (general practice) setting.

Key facts

Study ID

NCT00902304

Run by

Novartis Pharmaceuticals

People needed

2337

Starts

2009-07-01

Expected to finish

2011-07-01

Last updated by the study team

2012-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner

You may not qualify if…

• significantly elevated blood pressure (severe hypertension)
• requiring 3 or more antihypertensive drugs
• severe kidney disease or dialyses
• clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Professor Garry Jennings-Co Principal Investigator — Melbourne, Australia
• Professor Simon Stewart-Principal Investigator — Melbourne, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.